Evidence map›Paper›PMID 36144620›Full record

ArticleMolecules (Basel, Switzerland)2022

Benzo[k,l]xanthene Lignan-Loaded Solid Lipid Nanoparticles for Topical Application: A Preliminary Study.

Cristina Torrisi, Nunzio Cardullo, Stefano Russo, Alfonsina La Mantia, Rosaria Acquaviva, Vera Muccilli, Francesco Castelli, Maria Grazia Sarpietro

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Cristina TorrisiDepartment of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.
Nunzio CardulloDepartment of Chemical Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.ORCID 0000-0003-1480-0861
Stefano RussoDepartment of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.ORCID 0000-0001-7539-0427
Alfonsina La MantiaDepartment of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.
Rosaria AcquavivaDepartment of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.
Vera MuccilliDepartment of Chemical Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.ORCID 0000-0002-6212-5154
Francesco CastelliDepartment of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.
Maria Grazia SarpietroDepartment of Drug and Health Sciences, University of Catania, Viale Andrea Doria 6, 95125 Catania, Italy.ORCID 0000-0002-6799-4754
University of Catania · IT

Funding

MIUR ITALY PRIN 2017 . (Project No. 2017A95NCJ)
6 · The paper itself

Abstract

Skin is the first human barrier that is daily exposed to a broad spectrum of physical and chemical agents, which can increase reactive oxygen species (ROS) and lead to the formation of topical disorders. Antioxidant molecules, such as benzo[k,l]xanthene lignans (BXL), are ideal candidates to eliminate or minimize the effects of ROS. Herein, we aimed to formulate BXL-loaded solid lipid nanoparticles (SLN-BXL) to improve the bioavailability and interaction with the skin, and also to investigate the protective impact against intracellular ROS generation in HFF-1 in comparison with the drug-free situation. SLN-BXL were formulated using the PIT/ultrasonication method, and then were subjected to physicochemical characterizations, i.e., average size, zeta potential (ZP), polydispersity index (PDI), encapsulation efficiency (%EE), thermotropic behavior, and interaction with a biomembrane model. The results show a mean size around 200 nm, PDI of 0.2, and zeta potential of about -28 mV, with values almost unchanged over a period of three months, while the EE% is ≈70%. Moreover, SLN-BXL are able to deeply interact with the biomembrane model, and to achieve a double-action release in mildly hydrophobic matrices; the results of the in vitro experiments confirm that SLN-BXL are cell-safe and capable of attenuating the IL-2-induced high ROS levels. In conclusion, based on our findings, the formulation can be proposed as a candidate for a preventive remedy against skin disorders induced by increased levels of ROS.

Indexed as

LignansNanoparticlesAntioxidantsDrug CarriersHumansInterleukin-2LipidsLiposomesParticle SizeReactive Oxygen SpeciesXanthenesAntioxidantsDrug CarriersInterleukin-2LignansLipid NanoparticlesLipidsLiposomesReactive Oxygen SpeciesXanthenesbenzo[k,l]xanthene lignansbiomembrane modelDSCHFF-1SLN

Identifiers

PMID36144620
PMCPMC9503089
OpenAlexW4296020836

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.